Opioid Manufacturer Insys Declares Bankruptcy After Legal Trouble
In 2014, Forbes made "The Short Case for Insys Therapeutics," conceding that the company’s sales performance compensation system was "a fairly dangerous way to market" its opioid products, but asserting that there would only be danger if "medical sales of this drug...